3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp - Best Of!
Click Here to Manage Email Alerts
Learning Objectives:
Upon completion of this educational activity, the participant should be able to:
- Examine common signaling pathways that underlie chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
- Evaluate the mechanisms of cancer immunotherapies as they relate to both an antitumor response and the potential for autoimmunity to better manage patients with immune-related adverse events.
- Select treatment for patients with IMIDs based on the latest clinical evidence and patient characteristics.
- Communicate with patients regarding biosimilars to identify patients who may prefer a biosimilar over a reference biologic.
Click here to view this activity.
Overview:
Immune-mediated inflammatory diseases (IMIDs) are a group of clinically heterogeneous disorders, including rheumatoid arthritis, psoriasis, psoriatic arthritis, giant cell arteritis, systemic lupus erythematosus, and axial spondyloarthritis, that share a similar immunopathology. Recognizing the underlying immunopathological mechanisms of these disorders is essential for understanding how current and emerging therapies exert their effects. In this CME activity, recorded during the Association of Women in Rheumatology National Conference, experts in the field examine common signaling pathways in IMIDs, evaluate recent clinical evidence for available and emerging immune-based therapies that target these pathways, assess the utilization of biomarkers for the identification of patients with early inflammatory disease, and evaluate the mechanisms of cancer immunotherapies as they relate to both an antitumor response and the potential for autoimmunity.
Activity Chair: Grace C. Wright, MD, PhD, FACR
Type: Lecture
Articles/Items: 4
Release Date: 10/29/2019
Expiration Date: 10/28/2020
Credit Type: CME
Number of Credits: 2.75
Cost: Free
Provider: Vindico Medical Education
CME Information:
This continuing medical education activity is provided by Vindico Medical Education.
Support Statement: This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Target Audience: The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).